Observations on the Treatment of Rheumatoid Arthritis with Butazolidin

Currie, J.P.; Brown, Ryanne A.; Will, George F.

doi:10.1136/ard.12.2.88

Cited by 22 publications

(7 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Currie et al (1953) and Brodie, Lowman, Burns, Lee, Chenkin, Goldman, Weiner & Steele (1954) noted a relationship between plasma level and clinical effect but recently Davies, Orme, Williams, Hughes & Holt (1973) failed to demonstrate this relationship conclusively.…”

Section: Introductionmentioning

confidence: 97%

“…Phenylbutazone was introduced in 1952 and has established itself as an efficacious anti-inflammatory agent for the treatment of rheumatoid arthritis (Currie, Peebles-Brown & Will, 1953;Mason, Barnardo, Fox & Weatherall, 1967;Lewis-Faning & Fowler, 1971). Currie et al (1953) and Brodie, Lowman, Burns, Lee, Chenkin, Goldman, Weiner & Steele (1954) noted a relationship between plasma level and clinical effect but recently Davies, Orme, Williams, Hughes & Holt (1973) failed to demonstrate this relationship conclusively.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Phenylbutazone: a clinico‐pharmacological study in rheumatoid arthritis.

Brooks¹,

Walker²,

Wc³

1975

Brit J Clinical Pharma

View full text Add to dashboard Cite

A clinical trial of phenylbutazone in high dose (300 mg daily) and low dose (50 mg daily) is presented. 2. By analysis of the data by different methods, significant differences in clinical efficacy were shown between the two therapeutic regimes. 3. A relationship between the clinical effect and plasma level of phenylbutazone was demonstrated. 4. Some problems in the interpretation of plasma level‐ clinical effect correlates are discussed.

show abstract

Section: Introductionmentioning

confidence: 97%

Section: Introductionmentioning

confidence: 99%

Phenylbutazone: a clinico‐pharmacological study in rheumatoid arthritis.

Brooks¹,

Walker²,

Wc³

1975

Brit J Clinical Pharma

View full text Add to dashboard Cite

show abstract

“…In 3 of these cases (6 per cent ) the toxic reaction was of a major nature ancd necessitated discontinuing the drtug. 4. The average dose schedtule was 600 nmg.…”

Section: Toxicitymentioning

confidence: 99%

mentioning

confidence: 99%

“…4 Clinically, however it has been notedl that the miaximumtii benefit is most often reached in 36 to 48 hours after treatment has been started. 4 Because of its ability to produce sodium retentioni with edema, phenylbutazone has been susl)ected of possessing a hormonal action similar to cortisone or corticotropin. Studies have shown that phenylbutazone does not affect 17-Ketosteroid excretion, the eosinophil count, the insulin requiremlents in diabetics, nor is it able to stimulate the adrenal glands in hypophysectomized rats.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Evaluation of Phenylbutazone (Butazolidin) in the Treatment of Rheumatoid Spondylitis: Report of 50 Cases

1954

Ann Intern Med

View full text Add to dashboard Cite

Cortisone in Treatment of Rheumatoid Arthritis

Ward¹

1953

JAMA

View full text Add to dashboard Cite

Cortisone, initially known as 'compound E' was the medical sensation of the late 1940s and early 1950s. As early as April 1949, only a week after Philip Hench and colleagues first described the potential of 'compound E' at a Mayo Clinic seminar, the New York Times reported the drug's promise as a 'modern miracle' in the treatment of rheumatoid arthritis (RA). Given its high profile, it is unsurprising that historians of medicine have been attracted to study the innovation of cortisone. It arrived at the end of a decade of 'therapeutic revolutions', kicked off by penicillin transforming the treatment of bacterial infections and ending with hopes of a revolution in the treatment of non-infectious, chronic inflammatory diseases. Despite these studies of cortisone's introduction, few historians have taken the story forward and considered how cortisone was adopted and adapted into clinical practice. This article tells the longer of how the drug and its derivatives were taken from research laboratories and integrated into clinical practice; what has in recent decades become known as translational medicine (TM). In exploring cortisone's first decade in Britain, we focus specifically on its role in the treatment of RA. Our approach is always to consider cortisone's use in the context of other treatments available to clinicians, and at local and national institutional settings. We do not discuss the many other therapeutic uses of cortisone, which ranged for topical applications for skin diseases to the management of cancers, especially childhood leukaemia, nor do we discuss its close analogue ACTH-AdenoCorticoTropic Hormone. We think there are lessons in our study for TM policies today.

show abstract

Observations on the Treatment of Rheumatoid Arthritis with Butazolidin

Cited by 22 publications

References 13 publications

Phenylbutazone: a clinico‐pharmacological study in rheumatoid arthritis.

Phenylbutazone: a clinico‐pharmacological study in rheumatoid arthritis.

Evaluation of Phenylbutazone (Butazolidin) in the Treatment of Rheumatoid Spondylitis: Report of 50 Cases

Cortisone in Treatment of Rheumatoid Arthritis

Contact Info

Product

Resources

About